We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Rectangle Image
Product News

Applikon Biotechnology Announces Breakthrough for the BioProcessing Market

Rectangle Image
Product News

Applikon Biotechnology Announces Breakthrough for the BioProcessing Market

Applikon Biotechnology B.V. has announced the launch of i-ControlXL, a breakthrough for the BioProcessing market. Applikon’s products are used by the pharmaceutical, food and chemical and process industries as well as research centres.

According to Applikon, i-ControlXL is an easy-to-use platform and follows the Company’s 30 years’ experience in bio-process control. Specifically designed for the bio-process industry, it can offer industrial power, reliability and expandability using standard controllers (PLC) and distributed control systems (DCS).

i-ControlXL features a number of benefits for scientists including: intuitive navigation; a colour touch screen interface; options for bioreactor controls, pumps and sensors; the ability to use the same system to control autoclavable vessels, single-use bioreactors or SIP/CIP systems.

Benefits specific to engineers include: a choice of controllers including Siemens, Allen Bradley or Delta V; fieldbus technology; the power and reliably of an industrial controller; a design adhering to the S88 guidelines and open system architecture.

Hans van den Berg, [manager M&B], at Applikon Biotechnology commented, “Bioprocess related issues such as high-throughput screening, scaling up, scaling down and PAT are no longer a trend, but a must in this arena. A Manufacturing Execution Systems (MES) involves managing engineering changes and tracing material for regulatory compliance, conforming to increasingly stringent quality standards, delivering on schedule despite shrinking lead times, and reducing costs. It is becoming increasingly important. Our i-ControlXL platform addresses these issues.”

Advertisement